Competition and price among brand-name drugs in the same class: A systematic review of the evidence

BACKGROUND: Some experts have proposed combating rising drug prices by promoting brand–brand competition, a situation that is supposed to arise when multiple US Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for the same condition. However, numerous r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarpatwari, Ameet, DiBello, Jonathan, Zakarian, Marie, Najafzadeh, Mehdi, Kesselheim, Aaron S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667132/
https://www.ncbi.nlm.nih.gov/pubmed/31361747
http://dx.doi.org/10.1371/journal.pmed.1002872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667132/
https://www.ncbi.nlm.nih.gov/pubmed/31361747
http://dx.doi.org/10.1371/journal.pmed.1002872

Ejemplares similares